Top

03-02-2025 | Lymphoma | Review Article

Prognostic value of Glasgow prognostic score in hematological malignancies: a systematic review and meta-analysis

Authors: Lijun Jiang, Wenting Jin

Published in: International Journal of Hematology

Abstract

Objective

The Glasgow prognostic score (GPS) is used to predict the prognosis of several cancers. This first systematic review and meta-analysis evaluated the role of GPS in predicting overall survival (OS) and progression-free survival (PFS) in patients with hematological malignancies.

Methods

Embase, PubMed, CENTRAL, Scopus, and Google Scholar were screened for studies evaluating the prognostic role of GPS in hematological malignancies.

Results

Twelve studies were eligible. Meta-analysis showed that patients with GPS of ≥1 and ≥2 had worse OS than those with GPS of 0. We noted that both GPS scores of ≥1 and ≥2 were associated with significantly poor PFS in patients with hematological malignancies. Results remained robust on sensitivity analysis.

Conclusion

GPS can be used as a predictor of OS and PFS in patients with hematological malignancies. High GPS scores can lead to a twofold higher risk of poor OS and PFS.

Hu D, Shilatifard A. Epigenetics of hematopoiesis and hematological malignancies. Genes Dev. 2016;30:2021–41. https://doi.org/10.1101/gad.284109.116.CrossRefPubMedPubMedCentral

An Z-Y, Fu H, He Y, Zhu X, Huang Q-S, Wu J, et al. Projected global trends in hematological malignancies: incidence, mortality, and disability-adjusted life years from 2020 to 2030. Blood. 2023;142(Supplement 1):3810–3810. https://doi.org/10.1182/blood-2023-187856.CrossRef

U.S. Cancer Statistics Data Briefs. Hematologic Cancer Incidence, Survival, and Prevalence | CDC. 2022. https://www.cdc.gov/cancer/uscs/about/data-briefs/no30-hematologic-incidence-surv-prev.htm. Accessed 17 Feb 2024.

Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493-503. https://doi.org/10.1016/S1470-2045(14)70263-3.CrossRefPubMed

Rossi J-F, Lu ZY, Massart C, Levon K. Dynamic immune/inflammation precision medicine: the good and the bad inflammation in infection and cancer. Front Immunol. 2021;12: 595722. https://doi.org/10.3389/fimmu.2021.595722.CrossRefPubMedPubMedCentral

Qian S, Golubnitschaja O, Zhan X. Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J. 2019;10:365–81. https://doi.org/10.1007/s13167-019-00194-x.CrossRefPubMedPubMedCentral

Saluja S, Bansal I, Bhardwaj R, Beg MS, Palanichamy JK. Inflammation as a driver of hematological malignancies. Front Oncol. 2024;14:1347402. https://doi.org/10.3389/fonc.2024.1347402.CrossRefPubMedPubMedCentral

Chauhan R, Trivedi V. Inflammatory markers in cancer potential resources. Front Biosci. 2020;12:537. https://doi.org/10.2741/s537.CrossRef

Watson J, Salisbury C, Banks J, Whiting P, Hamilton W. Predictive value of inflammatory markers for cancer diagnosis in primary care: a prospective cohort study using electronic health records. Br J Cancer. 2019;120:1045–51. https://doi.org/10.1038/s41416-019-0458-x.CrossRefPubMedPubMedCentral

10.

Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14:2413–8. https://doi.org/10.1158/1055-9965.EPI-05-0316.CrossRefPubMed

11.

Zheng K, Liu X, Ji W, Lu J, Cui J, Li W. The efficacy of different inflammatory markers for the prognosis of patients with malignant tumors. J Inflamm Res. 2021;14:5769–85. https://doi.org/10.2147/JIR.S334941.CrossRefPubMedPubMedCentral

12.

Wang Y, Li P, Li J, Lai Y, Zhou K, Wang X, et al. The prognostic value of pretreatment Glasgow Prognostic Score in patients with esophageal cancer: a meta-analysis. Cancer Manag Res. 2019;11:8181–90. https://doi.org/10.2147/CMAR.S203425.CrossRefPubMedPubMedCentral

13.

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:1028–30. https://doi.org/10.1038/sj.bjc.6601242.CrossRefPubMedPubMedCentral

14.

Nie D, Zhang L, Wang C, Guo Q, Mao X. A high Glasgow prognostic score (GPS) or modified Glasgow prognostic score (mGPS) predicts poor prognosis in gynecologic cancers: a systematic review and meta-analysis. Arch Gynecol Obstet. 2020;301:1543–51. https://doi.org/10.1007/s00404-020-05581-8.CrossRefPubMed

15.

Qi F, Xu Y, Zheng Y, Li X, Gao Y. Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis. Ann Transl Med. 2019;7:531. https://doi.org/10.21037/atm.2019.09.160.CrossRefPubMedPubMedCentral

16.

Lu X, Guo W, Xu W, Zhang X, Shi Z, Zheng L, et al. Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients. Cancer Manag Res. 2019;11:229–49. https://doi.org/10.2147/CMAR.S185350.CrossRefPubMed

17.

Hu X, Wang Y, Yang W-X, Dou W-C, Shao Y-X, Li X. Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis. Cancer Manag Res. 2019;11:6163–73. https://doi.org/10.2147/CMAR.S208839.CrossRefPubMedPubMedCentral

18.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906. https://doi.org/10.1016/j.ijsu.2021.105906.CrossRefPubMed

19.

Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 30 Oct 2020.

20.

Akhtar OS, Modi K, Kim J, Skelson L, Smith E, Al-Jumayli MA, et al. Simple score of albumin and CRP predicts high-grade toxicity in patients with multiple myeloma receiving CAR-T therapy. Transplant Cell Ther. 2024;30:283.e1-283.e10. https://doi.org/10.1016/j.jtct.2023.12.010.CrossRefPubMed

21.

Iizuka-Honma H, Mitsumori T, Yoshikawa S, Takizawa H, Noguchi M. Factors associated with survival in patients with end-of-life hematological malignancies who received chemotherapy: a retrospective single-institution study. Am J Hosp Palliat Care. 2023;40:812–9. https://doi.org/10.1177/10499091221142502.CrossRefPubMed

22.

Li X, Zhang Y, Zhao W, Liu Z, Shen Y, Li J, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol. 2015;94:57–63. https://doi.org/10.1007/s00277-014-2167-0.CrossRefPubMed

23.

Li Y-J, Jiang W-Q, Huang J-J, Xia Z-J, Huang H-Q, Li Z-M. The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. Am J Hematol. 2013;88:394–9. https://doi.org/10.1002/ajh.23422.CrossRefPubMed

24.

Pénichoux J, Lanic H, Thill C, Ménard A-L, Camus V, Stamatoullas A, et al. Prognostic relevance of sarcopenia, geriatric, and nutritional assessments in older patients with diffuse large B-cell lymphoma: results of a multicentric prospective cohort study. Ann Hematol. 2023;102:1811–23. https://doi.org/10.1007/s00277-023-05200-x.CrossRefPubMedPubMedCentral

25.

Gebauer N, Mengler B, Kopelke S, Frydrychowicz A, Fürschke A, Hackenbroch C, et al. Prognostic impact of nutritional and inflammation-based risk scores in follicular lymphoma in the era of anti-CD20 targeted treatment strategies. J Cancer Res Clin Oncol. 2022;148:1789–801. https://doi.org/10.1007/s00432-021-03758-5.CrossRefPubMed

26.

Chen G-J, Wuxiao Z-J, Liang Y, Li C, Fu B-B, Wang H. Inflammation-based Glasgow prognostic score as an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma. Chin Med J (Engl). 2021;134:579–81. https://doi.org/10.1097/CM9.0000000000001345.CrossRefPubMed

27.

Witte HM, Bonorden B, Riecke A, Biersack H, Steinestel K, Merz H, et al. The Glasgow prognostic score at diagnosis is a predictor of clinical outcome in patients with multiple myeloma undergoing autologous haematopoietic stem cell transplantation. Cancers (Basel). 2020;12(4):921–9. https://doi.org/10.3390/cancers12040921.CrossRefPubMedPubMedCentral

28.

Kim D-Y, Song M-K, Chung J-S, Shin H-J, Yang DH, Lim S-N, et al. Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood Res. 2019;54:244–52. https://doi.org/10.5045/br.2019.54.4.244.CrossRefPubMedPubMedCentral

29.

Huh SJ, Oh SY, Lee S, Lee JH, Kim SH, Lee G-W, et al. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. Int J Hematol. 2019;110:438–46. https://doi.org/10.1007/s12185-019-02693-z.CrossRefPubMed

30.

Hao X, Wei Y, Wei X, Zhou L, Wei Q, Zhang Y, et al. Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma. Oncotarget. 2017;8:76740–8. https://doi.org/10.18632/oncotarget.20832.CrossRefPubMedPubMedCentral

31.

Raffetti E, Donato F, Castelnuovo F, Ladisa N, Paraninfo G, Di Filippo E, et al. The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study. J Transl Med. 2015;13:89. https://doi.org/10.1186/s12967-015-0446-8.CrossRefPubMedPubMedCentral

32.

Castillo JJ, Sinclair N, Beltrán BE, Song M-K, Ilic I, Leppa S, et al. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2013;37:386–91. https://doi.org/10.1016/j.leukres.2013.01.002.CrossRefPubMed

33.

Jiang Y, Eveillard J-R, Couturier M-A, Soubise B, Chen J-M, Gao S, et al. Asian population is more prone to develop high-risk myelodysplastic syndrome, concordantly with their propensity to exhibit high-risk cytogenetic aberrations. Cancers (Basel). 2021;13:481. https://doi.org/10.3390/cancers13030481.CrossRefPubMed

34.

McMillan DC, Crozier JEM, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22:881–6. https://doi.org/10.1007/s00384-006-0259-6.CrossRefPubMed

35.

Hirahara N, Matsubara T, Kaji S, Kawabata Y, Hyakudomi R, Yamamoto T, et al. Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score. Oncotarget. 2020;11:4169–77. https://doi.org/10.18632/oncotarget.27796.CrossRefPubMedPubMedCentral

36.

Stauder R, Augschoell J, Hamaker ME, Koinig KA. Malnutrition in older patients with hematological malignancies at initial diagnosis - association with impairments in health status systemic inflammation and adverse outcome. HemaSphere. 2020;4: e332. https://doi.org/10.1097/HS9.0000000000000332.CrossRefPubMedPubMedCentral

37.

Kim Y, Kim SJ, Hwang D, Jang J, Hyun SY, Kim YR, et al. The modified Glasgow prognostic scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen. Yonsei Med J. 2014;55:1568–75. https://doi.org/10.3349/ymj.2014.55.6.1568.CrossRefPubMedPubMedCentral

38.

Kanemasa Y, Shimoyama T, Sasaki Y, Sawada T, Omuro Y, Hishima T, et al. A convenient prognostic score consisting of the Glasgow prognostic score and serum lactate dehydrogenase predicts clinical outcome in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57:2460–3. https://doi.org/10.3109/10428194.2016.1143940.CrossRefPubMed

39.

Jung S-H, Yang D-H, Ahn J-S, Kim Y-K, Kim H-J, Lee J-J. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma. Acta Haematol. 2015;133:10–7. https://doi.org/10.1159/000360068.CrossRefPubMed

40.

Hong J, Yoon H-H, Ahn HK, Sym SJ, Park J, Park P-W, et al. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma. Acta Haematol. 2013;130:305–11. https://doi.org/10.1159/000353127.CrossRefPubMed

41.

Hu X, Feng X, Wang H, Miao Y, Lian X, Gao Q, et al. Association between serum albumin levels and survival in elderly patients with diffuse large B-cell lymphoma: a single-center retrospective study. Transl Cancer Res. 2023;12:1577–87. https://doi.org/10.21037/tcr-23-503.CrossRefPubMedPubMedCentral

42.

Liang-Fonseca J, Geissler K. Significance of C-reactive protein in patients with chronic myelomonocytic leukemia. Wien Med Wochenschr. 2023;173:15–20. https://doi.org/10.1007/s10354-022-00981-8.CrossRefPubMed

43.

Forte D, Krause DS, Andreeff M, Bonnet D, Méndez-Ferrer S. Updates on the hematologic tumor microenvironment and its therapeutic targeting. Haematologica. 2019;104:1928–34. https://doi.org/10.3324/haematol.2018.195396.CrossRefPubMedPubMedCentral

44.

Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21:27–39. https://doi.org/10.1016/j.cytogfr.2009.11.007.CrossRefPubMed

45.

Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6. https://doi.org/10.1038/nature04870.CrossRefPubMed

46.

Jiang J, Peng Z, Wang J, Chen M, Wan Y, Huang H, et al. C-reactive protein impairs immune response of CD8+ T cells via FcγRIIb-p38MAPK-ROS axis in multiple myeloma. J Immunother Cancer. 2023;11(10):e007593. https://doi.org/10.1136/jitc-2023-007593.CrossRefPubMedPubMedCentral

47.

Xiao Z, Li H, Xiao D, Liu Y, Chen X, Luo S, et al. Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study. BMC Cancer. 2022;22:1127. https://doi.org/10.1186/s12885-022-10231-0.CrossRefPubMedPubMedCentral

48.

Kim JE, Yoo C, Lee DH, Kim S-W, Lee J-S, Suh C. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol. 2010;89:391–7. https://doi.org/10.1007/s00277-009-0841-4.CrossRefPubMed

49.

Cherng NC, Asal NR, Kuebler JP, Lee ET, Solanki D. Prognostic factors in multiple myeloma. Cancer. 1991;67:3150–6. https://doi.org/10.1002/1097-0142(19910615)67:12%3c3150::aid-cncr2820671236%3e3.0.co;2-u.CrossRefPubMed

50.

Dambrós BF, Kobus RA, da Rosa R, Pereira LJ, Hinnig PF, Di Pietro PF, et al. The effect of oral dietary interventions on nutritional status and treatment tolerance in patients with hematologic neoplasms receiving chemotherapy: a systematic review. Nutr Rev. 2023. https://doi.org/10.1093/nutrit/nuad161.CrossRef

51.

Andersen S, Henden A, Staudacher H, Kennedy G, Gavin N. Fibre intake and supplementation during treatment for haematological malignancies: a scoping review. J Hum Nutr Diet. 2023;36:1982–91. https://doi.org/10.1111/jhn.13209.CrossRefPubMed

52.

Bargetzi L, Brack C, Herrmann J, Bargetzi A, Hersberger L, Bargetzi M, et al. Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial. Ann Oncol Off J Eur Soc Med Oncol. 2021;32:1025–33. https://doi.org/10.1016/j.annonc.2021.05.793.CrossRef

53.

Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila). 2016;9:895–905. https://doi.org/10.1158/1940-6207.CAPR-16-0209.CrossRefPubMed

54.

McNeil JJ, Gibbs P, Orchard SG, Lockery JE, Bernstein WB, Cao Y, et al. Effect of aspirin on cancer incidence and mortality in older adults. J Natl Cancer Inst. 2021;113:258–65. https://doi.org/10.1093/jnci/djaa114.CrossRefPubMed

Title: Prognostic value of Glasgow prognostic score in hematological malignancies: a systematic review and meta-analysis
Authors: Lijun Jiang
Wenting Jin
Publication date: 03-02-2025
Publisher: Springer Nature Singapore
Keywords: Lymphoma
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Multiple Myeloma
Leukemia
Published in: International Journal of Hematology
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-025-03935-z

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

12-12-2024
Lymphoma
News

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

12-12-2024
Mantle Cell Lymphoma
News

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

12-12-2024
Lymphoma
News

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote series | Spotlight on menopause

Springer Medicine

Prognostic value of Glasgow prognostic score in hematological malignancies: a systematic review and meta-analysis

Abstract

Objective

Methods

Results

Conclusion

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma